Ray Therapeutics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2607 7th St Ste B, Berkeley, California,...Phone Number
(858) 617-8610Website
www.raytherapeutics.comRevenue
$10.1 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Ray Therapeutics
Restore vision in patients with retinitis pigmentosa and other degenerative retinal diseases with our novel optogenetics approach.Explore more
Ray Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ray Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Ray Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Ray Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Ray Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Ray Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Ray Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Ray Therapeutics
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Ray Therapeutics launches new products
Check out if Ray Therapeutics is spiking on competitors!
Recommended Actions
Find VP level buyers at Ray Therapeutics
Find 3 more new buyers
Compare Similar Companies to Ray Therapeutics
Compare insights from companies similar to Ray Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Ray Therapeutics
$10.1M
11-50
Private
$345M
2021
Sonya WeigleChief of Staff & Chief Corporate Affairs Officer
Company Profile Activity
Activity Insights
Ray Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ray Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ray Therapeutics.
Ray Therapeutics financials insights
Gather financial insights about Ray Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Angel/Seed
$6M
2023
Series A
$100M
Grant
$4M
2025
Series A
$110M
2026
Series B
$125M
Ray Therapeutics Tech Stack
A closer look at the technologies used by Ray Therapeutics
Most Recent Scoops
Funding
Funding
Hiring Plans
Ray Therapeutics has more open roles in Legal than it has had at any time in the past 12 months.
Hiring Plans
Project
Laboratory Operations, Medical Research, Clinical Operations
Hiring Plans
Ray Therapeutics has more open roles in Medical & Health than it has had at any time in the past 12 months.
Hiring Plans
Project
Laboratory Operations, Medical Research, Clinical Operations
Ray Therapeutics News & Media
4BIO Capital portfolio company Ray Therapeutics announces upsized and oversubscribed ...
4BIO Capital continues support as founding investor, having backed Ray Therapeutics since seed funding in 2021 through Series A (2023)Proceeds to support two ongoing clinical-stage programs: RTx-015 for retinitis pigmentosa and RTx-021 for macular diseases including Stargardt disease and geographic atrophy AMD London, United Kingdom, 21 April 2026 - 4BIO Capital, a specialist biotech venture firm transforming innovative technologies into breakthrough precision therapies, today announces that its4BIO Capital portfolio company Ray Therapeutics announces upsized and oversubscribed $125 Million Series B financing for vision restoration treatments
London, United Kingdom, 21 April 2026 - 4BIO Capital, a specialist biotech venture firm transforming innovative technologies into breakthrough precision therapies, today announces that its portfolio company, Ray Therapeutics, an industry-leading clinical-stage biopharmaceutical company pioneering differentiated vision restoration therapies for those living with severe retinal degeneration, has closed an upsized and oversubscribed $125 million Series B financing.C-Ray Therapeutics (Chengdu) Co., Ltd Congratulates Partner Biokin Pharmaceutical on NMPA IND Approval of First Proprietary ARC Drug [177Lu]-BL-ARC001
CHENGDU, China, Oct. 11, 2025 /PRNewswire/ -- C-Ray Therapeutics (Chengdu) Co.,Ltd proudly congratulates its strategic partner, Biokin Pharmaceutical, on receiving implied approval from the National Medical Products Administration (NMPA) for the clinical trial application of [177Lu]-BL-ARC001 Injection, the company's first radiopharmaceutical and a Class 1 innovative biologic. This milestone approval marks Biokin's entry into the fast-growing Radiopharmaceutical Drug Conjugate (RDC) field and re
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ray Therapeutics
Sign Up For FreeTo access detailed company insights
Restore vision in patients with retinitis pigmentosa and other degenerative retinal diseases with our novel optogenetics approach.... Read More
